Sarepta Therapeutics Earnings Preview: Analysts Expect $1.01 EPS

Sarepta Therapeutics is set to release its quarterly earnings on August 6, 2025. Analysts expect an EPS of $1.01. The company's past performance has been mixed, with a 21.45% drop in share price following a missed EPS estimate last quarter. The share price is currently at $17.1, down 87.96% over the last 52-week period.

Sarepta Therapeutics (SRPT) is set to release its second-quarter 2025 earnings on August 6, 2025. Analysts expect the company to report an earnings per share (EPS) of $1.01 [2]. The company's past performance has been mixed, with a 21.45% drop in share price following a missed EPS estimate in the previous quarter. The share price is currently at $17.1, down 87.96% over the last 52-week period [2].

Sarepta Therapeutics' portfolio includes four marketed products targeting Duchenne muscular dystrophy (DMD), with Elevidys, Exondys 51, Vyondys 53, and Amondys 45 being the key offerings. The company reported preliminary net product revenues of $513 million for the second quarter, including $282 million from Elevidys sales [1]. However, the company has faced scrutiny due to three patient deaths linked to its gene therapy treatments, which were attributed to acute liver failure (ALF). The FDA cleared Elevidys for use in ambulatory patients after finding no link between the therapy and the Brazilian patient's death, and the company plans to resume delivery of Elevidys shipments soon [1].

Sarepta Therapeutics also announced a restructuring plan to save nearly $400 million annually starting in 2026. The company plans to lay off 36% of its workforce, around 500 employees, and reprioritize its pipeline, focusing on siRNA programs acquired from Arrowhead Pharmaceuticals (ARWR) [1].

The company's earnings surprise history shows mixed performance, with earnings missing estimates in two of the trailing four quarters, beating once, and meeting the same on another occasion, resulting in a negative average surprise of 194.53% [1]. Sarepta Therapeutics has an Earnings ESP of 0.00% and a Zacks Rank #4 (Sell) at present [1].

Investors should closely monitor Sarepta Therapeutics' earnings announcement for updates on Elevidys sales guidance and the company's restructuring plan. The stock has underperformed the industry this year, and the earnings surprise history suggests a potential for volatility in share price movements.

References:
[1] https://finance.yahoo.com/news/sarepta-report-q2-earnings-whats-150700650.html
[2] https://www.benzinga.com/insights/earnings/25/08/46869154/what-to-expect-from-sarepta-therapeuticss-earnings